Today, the PTAB invalidated 10 of the 15 challenged claims in Medtronic's '314 patent and declined to invalidate the challenged claims in the '756 patent over one Administrative Patent Judge's dissenting opinion. The district court case where Medtronic has asserted these patents is currently stayed based on these IPRs as well as pending IPRs on other Medtronic asserted patents.

Raymond W. Cohen, chief executive officer, said, "Axonics will continue to vigorously defend itself against Medtronic's claims while we remain focused on fulfilling our mission of changing the lives of patients suffering from bladder and bowel dysfunction."